Current and emerging treatment options in chronic myeloid leukemia

Elias Jabbour, Jorge E. Cortes, Francis J. Giles, Susan O'Brien, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the causative Bcr-Abl oncoprotein in CML, has resulted in hematologic and cytogenetic remissions in all phases of CML. A significant proportion of patients are resistant to imatinib or develop resistance during treatment. This is often a result of mutated forms of the Bcr-Abl oncoprotein to which imatinib is unable to bind. Several strategies have been developed to overcome the problem of imatinib resistance, including high-dose imatinib, novel targeted agents, and combination treatments. Novel agents include dasatinib, a potent TKI that inhibits several critical oncogenic proteins and which has recently been approved for patients with CML who are resistant or intolerant to imatinib; and nilotinib, a potent selective Bcr-Abl kinase inhibitor currently in clinical development. Other agents in development include SKI-606 and INNO-406. Stem cell transplantation remains a useful option, although it is not generally used as first-line treatment. Overall, there are an increasing number of treatment options available for patients with CML.

Original languageEnglish (US)
Pages (from-to)2171-2181
Number of pages11
JournalCancer
Volume109
Issue number11
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogene Proteins
Protein-Tyrosine Kinases
Therapeutics
Molecular Medicine
Leukemia, Myeloid, Chronic Phase
Stem Cell Transplantation
Cytogenetics
Imatinib Mesylate
Phosphotransferases
Proteins

Keywords

  • Dasatinib
  • Imatinib
  • Leukemia
  • Myeloid
  • Philadelphia-positive

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jabbour, E., Cortes, J. E., Giles, F. J., O'Brien, S., & Kantarjian, H. M. (2007). Current and emerging treatment options in chronic myeloid leukemia. Cancer, 109(11), 2171-2181. https://doi.org/10.1002/cncr.22661

Current and emerging treatment options in chronic myeloid leukemia. / Jabbour, Elias; Cortes, Jorge E.; Giles, Francis J.; O'Brien, Susan; Kantarjian, Hagop M.

In: Cancer, Vol. 109, No. 11, 01.06.2007, p. 2171-2181.

Research output: Contribution to journalReview article

Jabbour, E, Cortes, JE, Giles, FJ, O'Brien, S & Kantarjian, HM 2007, 'Current and emerging treatment options in chronic myeloid leukemia', Cancer, vol. 109, no. 11, pp. 2171-2181. https://doi.org/10.1002/cncr.22661
Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007 Jun 1;109(11):2171-2181. https://doi.org/10.1002/cncr.22661
Jabbour, Elias ; Cortes, Jorge E. ; Giles, Francis J. ; O'Brien, Susan ; Kantarjian, Hagop M. / Current and emerging treatment options in chronic myeloid leukemia. In: Cancer. 2007 ; Vol. 109, No. 11. pp. 2171-2181.
@article{ce2f863be4594fa38d805370f3b59a9f,
title = "Current and emerging treatment options in chronic myeloid leukemia",
abstract = "Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the causative Bcr-Abl oncoprotein in CML, has resulted in hematologic and cytogenetic remissions in all phases of CML. A significant proportion of patients are resistant to imatinib or develop resistance during treatment. This is often a result of mutated forms of the Bcr-Abl oncoprotein to which imatinib is unable to bind. Several strategies have been developed to overcome the problem of imatinib resistance, including high-dose imatinib, novel targeted agents, and combination treatments. Novel agents include dasatinib, a potent TKI that inhibits several critical oncogenic proteins and which has recently been approved for patients with CML who are resistant or intolerant to imatinib; and nilotinib, a potent selective Bcr-Abl kinase inhibitor currently in clinical development. Other agents in development include SKI-606 and INNO-406. Stem cell transplantation remains a useful option, although it is not generally used as first-line treatment. Overall, there are an increasing number of treatment options available for patients with CML.",
keywords = "Dasatinib, Imatinib, Leukemia, Myeloid, Philadelphia-positive",
author = "Elias Jabbour and Cortes, {Jorge E.} and Giles, {Francis J.} and Susan O'Brien and Kantarjian, {Hagop M.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1002/cncr.22661",
language = "English (US)",
volume = "109",
pages = "2171--2181",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Current and emerging treatment options in chronic myeloid leukemia

AU - Jabbour, Elias

AU - Cortes, Jorge E.

AU - Giles, Francis J.

AU - O'Brien, Susan

AU - Kantarjian, Hagop M.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the causative Bcr-Abl oncoprotein in CML, has resulted in hematologic and cytogenetic remissions in all phases of CML. A significant proportion of patients are resistant to imatinib or develop resistance during treatment. This is often a result of mutated forms of the Bcr-Abl oncoprotein to which imatinib is unable to bind. Several strategies have been developed to overcome the problem of imatinib resistance, including high-dose imatinib, novel targeted agents, and combination treatments. Novel agents include dasatinib, a potent TKI that inhibits several critical oncogenic proteins and which has recently been approved for patients with CML who are resistant or intolerant to imatinib; and nilotinib, a potent selective Bcr-Abl kinase inhibitor currently in clinical development. Other agents in development include SKI-606 and INNO-406. Stem cell transplantation remains a useful option, although it is not generally used as first-line treatment. Overall, there are an increasing number of treatment options available for patients with CML.

AB - Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the causative Bcr-Abl oncoprotein in CML, has resulted in hematologic and cytogenetic remissions in all phases of CML. A significant proportion of patients are resistant to imatinib or develop resistance during treatment. This is often a result of mutated forms of the Bcr-Abl oncoprotein to which imatinib is unable to bind. Several strategies have been developed to overcome the problem of imatinib resistance, including high-dose imatinib, novel targeted agents, and combination treatments. Novel agents include dasatinib, a potent TKI that inhibits several critical oncogenic proteins and which has recently been approved for patients with CML who are resistant or intolerant to imatinib; and nilotinib, a potent selective Bcr-Abl kinase inhibitor currently in clinical development. Other agents in development include SKI-606 and INNO-406. Stem cell transplantation remains a useful option, although it is not generally used as first-line treatment. Overall, there are an increasing number of treatment options available for patients with CML.

KW - Dasatinib

KW - Imatinib

KW - Leukemia

KW - Myeloid

KW - Philadelphia-positive

UR - http://www.scopus.com/inward/record.url?scp=34249096219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249096219&partnerID=8YFLogxK

U2 - 10.1002/cncr.22661

DO - 10.1002/cncr.22661

M3 - Review article

C2 - 17431887

AN - SCOPUS:34249096219

VL - 109

SP - 2171

EP - 2181

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -